Intensity Therapeutics Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
Employees
3
IPO date
Jun 30, 2023

Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market.

The company does not sell approved drugs yet, so it does not have a traditional commercial customer base. Today it funds its work through equity financing and, if it signs them, research or licensing partnerships with larger drug companies. If its treatments are approved in the future, it would likely make money from product sales, licensing fees, and possible royalties.

What makes Intensity Therapeutics different is that it is trying to turn a tumor into part of the treatment process instead of relying only on medicines that circulate through the whole body. That could fit alongside surgery, radiation, and other cancer drugs, and it gives the company a shot at becoming a specialty oncology developer focused on local tumor treatment rather than a broad drug maker.

Intensity Therapeutics Inc Investor Relations

Address
61 Wilton Road, 3rd Floor
Westport, Connecticut
United States of America

Business Segments

Cancer drug development

Intensity Therapeutics develops injectable cancer medicines that are designed to be placed directly into tumors and studied in clinical trials for solid tumors.

Customers and revenue model

Management

Mr. Lewis H. Bender M.A., M.B.A., M.S.

Founder, President, CEO & Chairman of the Board

Biography unavailable

Mr. Joseph Talamo CPA, M.B.A.

Chief Financial Officer

Biography unavailable

Mr. John Wesolowski CPA, M.B.A.

Principal Accounting Officer & Controller

Biography unavailable

Mr. James M. Ahlers

Executive Vice President of Corporate Finance

Biography unavailable

Mr. Brian Schwartz M.D.

Executive Vice President of Clinical Development

Biography unavailable

1 / 5